CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug

• click to rate

  Posted by Two Blokes Jun 23 - Filed in Stock - 4 views
  
  CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug, DefenCath.